Ellie J. C. Goldstein

Ellie J. C. Goldstein's AcademicInfluence.com Rankings

Medical

#2519

World Rank

#2947

Historical Rank

Dermatology

#51

World Rank

#68

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Ellie J. C. Goldstein Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ellie J. C. Goldstein's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Practice guidelines for the diagnosis and management of skin and soft-tissue infections. (2005) (2166)
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. (2014) (1240)
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. (2010) (1201)
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. (2014) (1034)
Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. (1999) (757)
IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. (2012) (511)
Propionibacterium acnes: from Commensal to Opportunistic Biofilm-Associated Implant Pathogen (2014) (441)
Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. (2010) (440)
Bacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents (2007) (439)
Bite wounds and infection. (1992) (367)
Microbiology of Animal Bite Wound Infections (2011) (292)
Effects of control interventions on Clostridium difficile infection in England: an observational study (2017) (252)
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis (2018) (242)
Evaluation of the E test for susceptibility testing of anaerobic bacteria (1991) (222)
Antianaerobic Antimicrobials: Spectrum and Susceptibility Testing (2013) (220)
Bacteriology of human and animal bite wounds (1978) (215)
Lactobacillus species: taxonomic complexity and controversial susceptibilities. (2015) (204)
Diabetic Foot Infections: Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases (1996) (182)
Two decades of imipenem therapy. (2006) (171)
National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004 (2007) (150)
Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. (2003) (149)
A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. (2017) (147)
Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). (2010) (142)
Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin (2012) (139)
Staphylococcus intermedius in canine gingiva and canine-inflicted human wound infections: laboratory characterization of a newly recognized zoonotic pathogen (1989) (134)
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide (2018) (124)
Is primary prevention of Clostridium difficile infection possible with specific probiotics? (2012) (121)
A central role for venom in predation by Varanus komodoensis (Komodo Dragon) and the extinct giant Varanus (Megalania) priscus (2009) (117)
Desulfovibrio desulfuricans Bacteremia and Review of Human Desulfovibrio Infections (2003) (115)
Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection (2008) (107)
Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. (2011) (100)
In Vitro Activities of Dalbavancin and Nine Comparator Agents against Anaerobic Gram-Positive Species and Corynebacteria (2003) (99)
Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection (2011) (97)
In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp (2004) (96)
In Vitro Activities of Ramoplanin, Teicoplanin, Vancomycin, Linezolid, Bacitracin, and Four Other Antimicrobials against Intestinal Anaerobic Bacteria (2003) (94)
NATIONAL SURVEY ON THE SUSCEPTIBILITY OF BACTEROIDES FRAGILIS GROUP: REPORT AND ANALYSIS OF TRENDS FOR 1997–2000 (2002) (93)
Bacteriology of rattlesnake venom and implications for therapy. (1979) (90)
Aetiology of antimicrobial-agent-associated colitis. (1978) (90)
Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis (2005) (88)
Periodontal Bacteria in Rabbit Mandibular and Maxillary Abscesses (2002) (84)
In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates (2003) (84)
Comparative In Vitro Activities of Ertapenem (MK-0826) against 1,001 Anaerobes Isolated from Human Intra-Abdominal Infections (2000) (83)
Antimicrobial Activities of Fidaxomicin (2012) (83)
Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. (2004) (80)
Biochemical Differentiation and Comparison of Desulfovibrio Species and Other Phenotypically Similar Genera (2005) (80)
Role of anaerobic bacteria in bite-wound infections. (1984) (79)
Dog bite wounds and infection: a prospective clinical study. (1980) (76)
Linezolid Activity Compared to Those of Selected Macrolides and Other Agents against Aerobic and Anaerobic Pathogens Isolated from Soft Tissue Bite Infections in Humans (1999) (76)
Saccharomyces cerevisiae infections in man. (1984) (75)
Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens (1995) (75)
Widespread use of fluoroquinolones versus emerging resistance in pneumococci. (2002) (74)
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria (1992) (71)
Fluoroquinolones and anaerobes. (2006) (71)
In Vitro Activity of Ceftobiprole against Aerobic and Anaerobic Strains Isolated from Diabetic Foot Infections (2006) (70)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates (2013) (69)
Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound Pathogens (2000) (69)
Emergence of fluoroquinolone resistance among Bacteroides species. (2003) (69)
National hospital survey of anaerobic culture and susceptibility methods: III. (2008) (68)
16S-23S rDNA internal transcribed spacer sequences for analysis of the phylogenetic relationships among species of the genus Fusobacterium. (2002) (68)
In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections (2006) (65)
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. (2004) (65)
Comparative Activity of Moxifloxacin in Vitro Against Obligately Anaerobic Bacteria (2000) (65)
In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections (2006) (65)
Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. (2012) (63)
Incidence and clinical significance of anaerobic bacteremia in a community hospital. (1993) (62)
Pathway to Prevention of Nosocomial Clostridium difficile Infection. (2015) (62)
Management of human and animal bite wounds. (1989) (61)
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans (1997) (60)
Synergistes Group Organisms of Human Origin (2006) (57)
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. (1996) (57)
Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Network of Long-Term Acute Care Hospitals (2016) (57)
Bacteriology of a Bear Bite Wound to a Human: Case Report (2004) (56)
Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria (2012) (56)
In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species (2011) (56)
Antibacterial activity of crotalid venoms against oral snake flora and other clinical bacteria. (1991) (56)
Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida (1988) (56)
Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds (1988) (55)
Activity of Gatifloxacin Compared to Those of Five Other Quinolones versus Aerobic and Anaerobic Isolates from Skin and Soft Tissue Samples of Human and Animal Bite Wound Infections (1999) (54)
In Vitro Activity of Gemifloxacin (SB 265805) against Anaerobes (1999) (53)
Clostridium aldenense sp. nov. and Clostridium citroniae sp. nov. Isolated from Human Clinical Infections (2006) (53)
Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. (2001) (53)
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin (2015) (52)
Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group (1988) (51)
A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). (2015) (51)
In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes (2006) (51)
Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents (2006) (50)
Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. (2009) (49)
Staphylococcus intermedius: clinical presentation of a new human dog bite pathogen. (1989) (49)
Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosa (2009) (49)
Beyond the target pathogen: ecological effects of the hospital formulary (2011) (49)
Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibaculum rodentium. (2017) (48)
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. (2002) (47)
Infections caused by Klebsiella ozaenae: a changing disease spectrum (1978) (47)
Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009. (2017) (47)
Anaerobic bacteria cultured from the tongue dorsum of subjects with oral malodor. (2003) (46)
Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals (1985) (46)
Characterization of saccharolytic Bacteroides and Prevotella isolates from infected dog and cat bite wounds in humans (1997) (46)
In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms (2002) (45)
Resistance Trends in Antimicrobial Susceptibility of Anaerobic Bacteria, Part I (2011) (45)
In Vitro Activity of Ceftaroline against 623 Diverse Strains of Anaerobic Bacteria (2010) (44)
Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains. (2014) (44)
In Vitro Activities of Doripenem and Six Comparator Drugs against 423 Aerobic and Anaerobic Bacterial Isolates from Infected Diabetic Foot Wounds (2007) (44)
Activities of Telithromycin (HMR 3647, RU 66647) Compared to Those of Erythromycin, Azithromycin, Clarithromycin, Roxithromycin, and Other Antimicrobial Agents against Unusual Anaerobes (1999) (43)
In Vitro Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria (2013) (42)
Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship. (2015) (42)
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. (1993) (41)
1044Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial (2014) (41)
Comparative In Vitro Activities of XRP 2868, Pristinamycin, Quinupristin-Dalfopristin, Vancomycin, Daptomycin, Linezolid, Clarithromycin, Telithromycin, Clindamycin, and Ampicillin against Anaerobic Gram-Positive Species, Actinomycetes, and Lactobacilli (2005) (40)
Pelvic Abscess Due to Ochrobactrum anthropi in an Immunocompetent Host: Case Report and Review of the Literature (2006) (40)
Characterization of a β-lactamase from Clostridium clostridioforme (1994) (39)
National hospital survey of anaerobic culture and susceptibility testing methods: results and recommendations for improvement (1992) (39)
Susceptibility of bite wound bacteria to seven oral antimicrobial agents, including RU-985, a new erythromycin: considerations in choosing empiric therapy (1986) (39)
In Vitro Activity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes (2011) (39)
Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. (2011) (39)
Outpatient Therapy of Bite Wounds (1987) (38)
Frequency of isolation of Porphyromonas species from infected dog and cat bite wounds in humans and their characterization by biochemical tests and arbitrarily primed-polymerase chain reaction fingerprinting. (1996) (38)
In Vitro Activities of Garenoxacin (BMS 284756) against 108 Clinical Isolates of Gardnerella vaginalis (2002) (37)
Pelvic Abscess Due to Ochrobactrum anthropi in an Immunocompetent Host: Case Report and Review of the Literature (2006) (37)
Comparative in vitro activities of azithromycin, Bay y 3118, levofloxacin, sparfloxacin, and 11 other oral antimicrobial agents against 194 aerobic and anaerobic bite wound isolates (1995) (37)
Fatal sepsis due to a beta-lactamase-producing strain of Fusobacterium nucleatum subspecies polymorphum. (1995) (36)
Ridinilazole: a novel therapy for Clostridium difficile infection. (2016) (36)
Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. (2009) (36)
Susceptibility of Eikenella corrodens to Ten Cephalosporins (1978) (36)
New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds. (1998) (35)
Comparative Susceptibilities of Anaerobic Bacteria to Metronidazole, Ornidazole, and SC-28538 (1978) (35)
Fusobacterium canifelinum sp. nov., from the oral cavity of cats and dogs. (2004) (35)
A selective medium for Fusobacterium spp. (1991) (34)
Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinations (1991) (34)
Human and animal bite wounds. (1987) (34)
Infective endocarditis associated with spondylodiscitis and frequent secondary epidural abscess. (2008) (34)
First report of Parabacteroides goldsteinii bacteraemia in a patient with complicated intra-abdominal infection. (2010) (34)
In vitro activity of azithromycin and nine comparator agents against 296 strains of oral anaerobes and 31 strains of Eikenella corrodens. (2006) (33)
Probiotics and prevention of Clostridium difficile infection. (2017) (33)
Evaluation of the RapID CB Plus System for Identification of Corynebacterium Species and Other Gram-Positive Rods (1998) (32)
Pasteurellamultocida subsp.multocida and P. multocida subsp.septica Differentiation by PCR Fingerprinting and α-Glucosidase Activity (2001) (32)
Activities of Gemifloxacin (SB 265805, LB20304) Compared to Those of Other Oral Antimicrobial Agents against Unusual Anaerobes (1999) (32)
Comparative In Vitro Activities of ABT-773 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft-Tissue Animal and Human Bite Wound Infections (2000) (32)
Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines. (2016) (32)
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. (2002) (32)
Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. (2002) (31)
Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis. (2009) (31)
Bacteriology of human bite wound infections. (2003) (30)
Peptoniphilus coxii sp. nov. and Peptoniphilus tyrrelliae sp. nov. isolated from human clinical infections. (2012) (30)
Simian bites and bacterial infection. (1995) (30)
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. (1998) (30)
Infections caused by Actinomyces viscosus. (1981) (29)
In vitro activities of tinidazole and metronidazole against Clostridium difficile, Prevotella bivia and Bacteroides fragilis. (2005) (29)
In Vitro Activities of the Des-Fluoro(6) Quinolone BMS-284756 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft Tissue Animal and Human Bite Wound Infections (2002) (29)
Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. (1993) (29)
Survival of Aerobic and Anaerobic Bacteria in Purulent Clinical Specimens Maintained in the Copan Venturi Transystem and Becton Dickinson Port-a-Cul Transport Systems (2000) (28)
Comparative In Vitro Activities of Retapamulin (SB-275833) against 141 Clinical Isolates of Propionibacterium spp., Including 117 P. acnes Isolates (2006) (28)
Recovery of an unusual Flavobacterium group IIb-like isolate from a hand infection following pig bite (1990) (28)
Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens. (2000) (27)
Susceptibility of Eikenella corrodens to penicillin, apalcillin, and twelve new cephalosporins (1984) (27)
Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. (2013) (26)
Infections following clenched-fist injury: a new perspective. (1978) (26)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence (2013) (26)
ANAEROBIC AND AEROBIC BACTERIOLOGY OF THE SALIVA AND GINGIVA FROM 16 CAPTIVE KOMODO DRAGONS (VARANUS KOMODOENSIS): NEW IMPLICATIONS FOR THE “BACTERIA AS VENOM” MODEL (2013) (26)
Comparative in vitro activities of amoxicillin-clavulanic acid and imipenem against anaerobic bacteria isolated from community hospitals (1986) (26)
Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides (1996) (25)
Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates (1997) (25)
United States National Hospital Survey of anaerobic culture and susceptibility methods, II. (1995) (24)
Broth Microdilution and Disk Diffusion Tests for Susceptibility Testing of Pasteurella Species Isolated from Human Clinical Specimens (2005) (24)
Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents (1993) (24)
In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria. (2000) (24)
In Vitro Activity of TD-1792, a Multivalent Glycopeptide-Cephalosporin Antibiotic, against 377 Strains of Anaerobic Bacteria and 34 Strains of Corynebacterium Species (2012) (24)
Cephalosporin therapy for salmonellosis. Questions of efficacy and cross resistance with ampicillin. (1986) (24)
Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Rationale for selective decontamination of the digestive tract. (1987) (24)
Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience (2015) (23)
Re-assessment of phenotypic identifications of Bacteroides putredinis to Alistipes species using molecular methods. (2011) (22)
In Vitro Activities of Telithromycin and 10 Oral Agents against Aerobic and Anaerobic Pathogens Isolated from Antral Puncture Specimens from Patients with Sinusitis (2003) (22)
Characterization of the Bacteroides fragilis pathogenicity island in human blood culture isolates. (2006) (22)
Difficulty in the identification and differentiation of clinically relevant Ochrobactrum species. (2007) (22)
Necrotizing Soft Tissue Infections. (2020) (21)
Whole-Genome Sequencing To Identify Drivers of Carbapenem-Resistant Klebsiella pneumoniae Transmission within and between Regional Long-Term Acute-Care Hospitals (2019) (21)
In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species. (2018) (21)
Failure of vancomycin prophylaxis and treatment for Actinobacillus actinomycetemcomitans endocarditis (1986) (21)
Bacterial counts from five over-the-counter probiotics: are you getting what you paid for? (2014) (21)
Fastidious anaerobe agar compared with Wilkins-Chalgren agar, brain heart infusion agar, and brucella agar for susceptibility testing of Fusobacterium species (1990) (21)
Nutrition in the geriatric patient. (1990) (21)
In Vitro Activities of ABT-492, a New Fluoroquinolone, against 155 Aerobic and 171 Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis (2003) (21)
Molecular characterization and antimicrobial susceptibilities of extra-intestinal Clostridium difficile isolates. (2007) (21)
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016 (2019) (20)
Comparative In Vitro Activities of GSK2251052, a Novel Boron-Containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms (2013) (20)
16S-23S rRNA gene internal transcribed spacer sequences for analysis of the phylogenetic relationships among species of the genus Porphyromonas. (2005) (20)
Comparative In Vitro Activities of Ertapenem (MK-0826) against 469 Less Frequently Identified Anaerobes Isolated from Human Infections (2002) (20)
Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial (2016) (20)
Effect of carbon dioxide on in vitro susceptibility of anaerobic bacteria to erythromycin (1981) (20)
Characterization of indole-negative Bacteroides fragilis group species with use of polymerase chain reaction fingerprinting and resistance profiles. (1996) (19)
Comparative In Vitro Activities of Amoxicillin-Clavulanate against Aerobic and Anaerobic Bacteria Isolated from Antral Puncture Specimens from Patients with Sinusitis (1999) (19)
Short prereduced anaerobically sterilized (PRAS) biochemical scheme for identification of clinical isolates of bile-resistant Bacteroides species (1990) (19)
In vitro activity of 11 antibiotics against 74 anaerobes isolated from pediatric intra-abdominal infections. (2006) (19)
C. difficile infection (CDI) in a long-term acute care facility (LTAC). (2009) (19)
Activity of a novel carbapenem, doripenem, against anaerobic pathogens. (2009) (19)
Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015. (2018) (18)
Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains (2017) (18)
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. (2002) (18)
Erythromycin for anaerobic pleuropulmonary and soft-tissue infections. (1979) (17)
Evaluation of Cycloserine-Cefoxitin Fructose Agar (CCFA), CCFA with Horse Blood and Taurocholate, and Cycloserine-Cefoxitin Mannitol Broth with Taurocholate and Lysozyme for Recovery of Clostridium difficile Isolates from Fecal Samples (2013) (17)
Bactericidal Activities of Methoxyfluoroquinolones Gatifloxacin and Moxifloxacin against Aerobic and Anaerobic Respiratory Pathogens in Serum (2003) (17)
Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections (2017) (17)
Growth characteristics and a novel method for identification (the WEE-TAB system) of Porphyromonas species isolated from infected dog and cat bite wounds in humans (1997) (17)
Identification and strain differentiation of 'Bacteroides fragilis group' species and Prevotella bivia by PCR fingerprinting. (1995) (16)
Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children. (1995) (16)
Survival of anaerobic bacteria in various thioglycolate and chopped meat broth formulations (1995) (16)
Ceftaroline versus Isolates from Animal Bite Wounds: Comparative In Vitro Activities against 243 Isolates, Including 156 Pasteurella Species Isolates (2012) (16)
Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group (1991) (16)
Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus. (2008) (16)
In Vitro Activities of Iodonium Salts against Oral and Dental Anaerobes (2004) (15)
In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. (2002) (15)
Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting (2017) (15)
Reproducibility of broth microdilution and comparison to agar dilution for testing CB-183,315 against clinical isolates of Clostridium difficile. (2011) (15)
Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus (1985) (14)
Clostridium difficile: improving the prevention paradigm in healthcare settings (2014) (14)
Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates (2018) (14)
Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures. (2005) (14)
Corrigendum: Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibacterium rodentium. (2017) (14)
Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections. (2013) (14)
Characterization of Bacteroides forsythus Strains from Cat and Dog Bite Wounds in Humans and Comparison with Monkey and Human Oral Strains (1999) (14)
Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens. (2007) (13)
Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability (2016) (13)
Selected nonsurgical anaerobic infections: therapeutic choices and the effective armamentarium. (1994) (12)
Characteristics of Fusobacterium ulcerans, a New and Unusual Species Compared with Fusobacterium varium and Fusobacterium mortiferum (1999) (12)
Pathologic rupture of the spleen due to Salmonella dublin infection. (1985) (12)
Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. (2008) (12)
In Vitro Activities of Garenoxacin (BMS-284756) against 170 Clinical Isolates of Nine Pasteurella Species (2002) (12)
Clinical Anaerobic Infections (1999) (12)
Genetic Determinant of Intrinsic Quinolone Resistance in Fusobacterium canifelinum (2005) (12)
Clostridium innocuum bacteremia secondary to infected hematoma with gas formation in a kidney transplant recipient (2003) (12)
A review of three cases of Clostridium aldenense bacteremia. (2010) (12)
Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use (2021) (12)
Current concepts on animal bites: bacteriology and therapy. (1999) (12)
Occurrence of Bacteroides fragilis enterotoxin gene-carrying strains in Germany and the United States. (2000) (11)
Infectious complications and therapy of bite wounds. (1989) (11)
Review of the in vitro activity and potential clinical efficacy of levofloxacin in the treatment of anaerobic infections. (2003) (11)
Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media. (2002) (11)
Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole (1991) (10)
Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species. (1996) (10)
Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile. (2008) (10)
Evaluation of a novel specimen transport system (Venturi Transystem) for anaerobic bacteria. (1997) (10)
Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media. (2002) (10)
In Vitro Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds (2017) (9)
Bilophila wadsworthia clinical isolates compared by polymerase chain reaction fingerprinting. (1997) (9)
Occurrence of Bacteroides fragilisEnterotoxin Gene-Carrying Strains in Germany and the United States (2000) (9)
Patient and Microbial Genomic Factors Associated with Carbapenem-Resistant Klebsiella pneumoniae Extraintestinal Colonization and Infection (2021) (9)
Review of the Comparative In vitro Susceptibilities of Lower Female Genital Tract Pathogens to Older and Newer Fluoroquinolones (2000) (9)
In Vitro Activities of a New Des-Fluoroquinolone, BMS 284756, and Seven Other Antimicrobial Agents against 151 Isolates of Eikenella corrodens (2002) (9)
The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems. (2017) (8)
Comparative phospholipid analogue distributions of Porphyromonas gingivalis isolated from cats in Australia and the USA. (2001) (8)
Effect of Carbon Dioxide on Erythromycin (1983) (8)
Characterization of a beta-lactamase from Clostridium clostridioforme. (1994) (8)
Susceptibility of Gardnerella vaginalis to cephradine (1983) (8)
Anaerobes under assault: from cottage industry to industrialization of medicine and microbiology. (1995) (8)
Characterization of Bilophila wadsworthia Isolates Using PCR Fingerprinting (1999) (8)
Empyema due to Bacteroides gracilis: case report and in vitro susceptibilities to eight antimicrobial agents. (1993) (7)
Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. (2019) (7)
Therapy of Clostridium difficile infection: perspectives on a changing paradigm (2013) (7)
Mobilization and prevalence of a Fusobacterial plasmid. (2010) (7)
In Vitro Activities of ABT-773, a New Ketolide, against Aerobic and Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis (2001) (7)
Perinatal Clostridium perfringens Infection (1981) (7)
Use of polymerase chain reaction fingerprinting to compare clinical isolates of Bacteroides fragilis and Bacteroides thetaiotaomicron from Germany and the United States. (1997) (7)
Enhanced Clostridioides difficile Infection Prevention With a Pharmacy-Controlled Policy That Adds a 3-Strain Lactobacillus Probiotic Concomitantly to Antibiotic Therapy (2021) (6)
Diseases Transmitted by Cats. (2015) (6)
PCR fingerprinting analysis for differentiation of Streptococcus pneumoniae reinfection versus relapse. (2000) (6)
Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums (2020) (5)
In Vitro Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, Prevotella, Porphyromonas, and Veillonella Species (2020) (5)
Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014 (2017) (5)
In vitro activity of DS-2969b and comparator antimicrobial agents against Clostridioides (Clostridium) difficile, methicillin-resistant Staphylococcus aureus, and other anaerobic bacteria. (2018) (5)
Animal Bites and Zoonoses: From A to Z: Alligators to Zebras (2015) (5)
Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI) (2020) (5)
Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals (1985) (5)
Successful treatment of Mycobacterium terrae complex infection of the knee. (2012) (5)
Cefoxitin in the treatment of aerobic and anaerobic infections. Prospective correlation of in vitro susceptibility methods with clinical outcome. (1990) (5)
Epidemiologic trends in Clostridioides difficile isolate ribotypes in United States from 2011 to 2016. (2020) (4)
Activity of garenoxacin against 536 unusual anaerobes including 128 recovered from acute pelvic infections. (2011) (4)
Distribution of Fusobacterium Species and Prevalence of Beta-Lactamase Production at a Community Hospital (1999) (4)
The Times They Are A-Changin’: New Antibacterials for Skin and Skin Structure Infections (2015) (4)
Antimicrobial Resistance of Anaerobic Bacteria (2008) (4)
Anti-anaerobic activity of serum from patients treated with tigecycline for skin/soft tissue infections. (2011) (4)
Susceptibility testing of anaerobes--fact, fancy, and wishful thinking. (1989) (4)
Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection (2019) (4)
Bulleidia extructa prosthetic hip infection after a dental procedure: Potential need for prophylaxis. (2020) (3)
Serum Bactericidal Activity of Trovafloxacin Against Selected Anaerobic Pathogens (2001) (3)
In vitro chemotherapeutic combinations against isoniazid-resistant Mycobacterium tuberculosis and Mycobacterium fortuitum. (1971) (3)
In vitro stability of three oral vancomycin preparations stored at 2- 5 °C and ambient room temperature for up to 60 days against 100 Clostridioides (Clostridium) difficile and 51Staphylococcus aureus strains. (2018) (3)
Comparative in vitro activity of imipenem and 15 other antimicrobial agents against clinically important aerobic and anaerobic bacteria. (1988) (3)
Prevention of bacterial resistance in urinary tract infections. (1991) (3)
Absence of Tolerance to Cefoxitin in Anaerobic Bacteria (1981) (3)
Efficacy of bezlotoxumab in trial participants infected with Clostridioides difficile strain BI associated with poor outcomes. (2020) (3)
Immunoblot characterization of Porphyromonas species from infected dog and cat bite wounds in humans. (1997) (3)
Escherichia coli resistant to ampicillin/sulbactam. (1992) (3)
Fever in a couple vacationing in the mountains of southern California. (1992) (3)
Sequence conservation and distribution of the fusobacterial immunosuppressive protein gene, fipA. (2002) (3)
Bundling Probiotics With Antimicrobial Stewardship Programs for the Prevention of Clostridiodes difficile Infections in Acute Care Hospitals (2020) (3)
Trends in Carbapenem Susceptibility of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates From Long-Term Acute Care Hospitals Across the United States-An Analysis of Antibiograms (2015) (2)
anaerobic bite wound isolates. ciprofloxacin against 387 aerobic and levofloxacin, ofloxacin, sparfloxacin, and Comparative in vitro activities of DU-6859a, (2013) (2)
In Vitro Activities of Pexiganan and 10 Comparator Antimicrobials against 502 Anaerobic Isolates Recovered from Skin and Skin Structure Infections (2017) (2)
The importance of susceptibility testing of anaerobes: A clinician's perspective (1992) (2)
Isolation of Eikenella corrodens from Pulmonary Infections1, 2 (2015) (2)
Bulleidia extructa: An underappreciated anaerobic pathogen. (2021) (2)
Antimicrobial Stewardship: The View From California (2012) (2)
Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction. (2004) (2)
20 – Bite Infections (1989) (1)
LEGIONNAIRES' DISEASE Finding Answers to the Riddle (1980) (1)
Machine learning models to identify patient and microbial genetic factors associated with carbapenem-resistant Klebsiella pneumoniae infection (2020) (1)
Animal Bites (1985) (1)
Antimicrobial management of respiratory infections in SARS-CoV-2 patients: Clinical and ASP conundrums (2020) (1)
Binding of Cycloheximide to Ribosomes from Wild-Type and Mutant Strains of Saccharomyces cerevisiae (1981) (1)
In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species. (2017) (1)
In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates (2003) (1)
Introduction and Dedication (2002) (1)
Role of antimicrobial stewardship (AMS) & strategies for appropriate antimicrobial therapy (2014) (1)
Comparative "real world" in vitro activity of two new antimicrobials (ceftolozane-tazobactam and ceftazidime-avibactam) against ceftazidime non-susceptible Pseudomonas aeruginosa and resistant Enterobacteriaceae from california long term acute care hospitals (2018) (1)
Effect on antimicrobial usage and the in vitro susceptibility on aerobic, gram-negative rods after the introduction of ertapenem onto a hospital formulary (2006) (1)
Comparative in vitro activity of gemifloxacin against aerobic and anaerobic pathogens isolated from antral sinus punctures from patients with sinusitis (2001) (1)
Management of human and animal bite wounds. (1985) (1)
In Vitro Activities of Newer Quinolones against Bacteroides Group Organisms (2003) (1)
Differentiation of clinical Bacteroides ovatus isolates using RNA gene size polymorphisms (1997) (1)
In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone, Compared to Other Fluoroquinolones Against Anaerobic Bacteria (2000) (1)
Treatment of Clostridium difficile Infection With Tigecycline: Proof of Concept Study (2013) (0)
Chapter 68 – Infections from pets (2010) (0)
Anaerobic blood cultures: A consensus group report (1997) (0)
Trends in the Antimicrobial Susceptibility of Anaerobic Bacteria (2007) (0)
Risk Factors for Colistin-Resistant Carbapenem-Resistant Klebsiella pneumoniae in the Postacute Care Setting (2022) (0)
CLINICAL RESEARCH IN THE PRIVATE PRACTICE OF INFECTIOUS DISEASES (1992) (0)
Clinical Efﬁcacy and Correlation of Clinical Outcomes With In Vitro Susceptibility for Anaerobic Bacteria in Patients With Complicated Intra-abdominal Infections Treated With Moxiﬂoxacin (2011) (0)
Choosing antimicrobials for anaerobic infections (2009) (0)
Fusobacteria behaving badly: Masquerading strains of strictly anaerobic Escherichia coli misidentified due to the deletion of the hemB gene. (2022) (0)
73 – Infections from Pets (2017) (0)
Role of Asymptomatic Carriers in Long-Term Care Facility Clostridioides (Clostridium) difficile Transmission (2019) (0)
ANAEROBIC INFECTION FOLLOWING ANIMAL BITES (1993) (0)
Characterization of Bacteroides forsythus Strains from Cat and Dog Bite Wounds in Humans and Comparison with Monkey and Human Oral Strains (2000) (0)
Diabetic foot infection: Conservative treatment outcomes (2000) (0)
Infectious Diseases Society of America and health care reform. (1994) (0)
Phospholipid Analogue Profiles of HumanPorphyromonas gingivalisIsolates from Different Geographical Locations (2003) (0)
206Implementing an Antimicrobial Stewardship Program (2014) (0)
292. How Do Komodo Dragons Kill Their Prey?: Lack of Role for Oral Flora in Predation (2012) (0)
Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difﬁcile Recurrence (2014) (0)
Trends in In Vitro Susceptibility to Antimicrobial Agents (2007) (0)
International Congress on Anaerobic Bacteria and Anaerobic Infections (1997) (0)
Characterization of Bacteroides fragilis group species using PCR fingerprinting and antimicrobial resistance patterns (1996) (0)
Combating the ascendancy of MRSA: Early efforts in eradication of colonization (2007) (0)
Clinical Infectious Disease: Human and Animal Bites (2008) (0)
Treatment of Anaerobic Pleuropulmonary and Soft-Tissue Infections-Reply (1980) (0)
Use of gemifloxacinforbindelser against bacteria (2000) (0)
Methicillin-resistant staphylococcus aureus (2000) (0)
Clostridium difficile infection in Western countries: Under diagnoses, epidemiology & evolving therapies (2015) (0)
Reply to Solnick. (2015) (0)
1774. Ridinilazole (RDZ) for Clostridium difficile infection (CDI): Correlation of In Vitro Spectrum of Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical Trial (2018) (0)
Characterization of a (Mactamase from Clostridium clostridioforme (1994) (0)
1261. Antimicrobial Susceptibilities of Carbapenem-Resistant Klebsiella pneumoniae (CRKP) Isolates from a Multi-state Network of Long-term Acute Care Hospitals (LTACHs) (2021) (0)
Pulmonary Infections Caused by Lancefield Group A Beta-Hemolytic Streptococcus (1994) (0)
Phospholipid Analogue Profiles of Human Porphyromonas gingivalis Isolates from Different Geographical Locations (2003) (0)
Comparative in vitro activity of ciprofloxacin cip ofloxacin ofx ci 960 ci 990 sparfloxacin spx temafloxacin tmx and win 57273 against 293 clinical isolates of anaerobic bacteria (1991) (0)
SPECIAL SECTION: CLINICAL PRACTICE (2000) (0)
Should Amoxicillin Versus Amoxicillin-Clavulanate Be Used for Initial Empiric Antimicrobial Therapy of ABRS in Children ? (2012) (0)
Comparative susceptibility of Gemella morbillorum to 13 antimicrobial agents. (2022) (0)
Perils of Pfisteria (2000) (0)
1279. Risk Factors for Colistin Resistance Among Carbapenem-Resistant Klebsiella pneumoniae (CRKP) in a Network of Long-term Acute Care Hospitals (LTACHs) (2021) (0)
Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability (2011) (0)
In Vitro Susceptibilities of the Bacteroides fragilis Group Species: Change in Isolation Rates Significantly Affects Overall Susceptibility Data (2002) (0)
Multidrug-Resistant Infections Evaluating the Role of New β-Lactam Agents for Uncommon Pathogens (2019) (0)
Clinical Infectious Disease: Animal and human bites (2015) (0)
Characterization of resistance to newer antimicrobials among carbapenem-resistant Klebsiella pneumoniae in the post-acute-care setting. (2022) (0)
Leucyl-tRNA Synthetase Inhibitor, against GSK2251052, a Novel Boron-Containing Activities of In Vitro Comparative (2014) (0)
Lactobacillus Bacteremia and Probiotics: A Review (2023) (0)
Infection control. Human and animal bite wounds. (1987) (0)
CLINICAL P RACTICE INVITED A RTICLE (2005) (0)
Coccidioidal Peritonitis: A Review of 17 Cases (2022) (0)
AUTHOR'S CORRECTION Pelvic Abscess Due to Ochrobactrum anthropi in an Immunocompetent Host: Case Report and Review of the Literature (2007) (0)
Anaerobic antimicrobial susceptibilities and therapeutic strategies: a United States perspective (1997) (0)
305 – Diseases Caused by Non–Spore-Forming Anaerobic Bacteria (2012) (0)
Patient and Microbial Genomic Factors Associated with Carbapenem-Resistant <named-content content-type='genus-species'>Klebsiella pneumoniae</named-content> Extraintestinal Colonization and Infection (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ellie J. C. Goldstein?

Ellie J. C. Goldstein is affiliated with the following schools:

University of California, Los Angeles

Ellie J. C. Goldstein's Academic­Influence.com Rankings

Why Is Ellie J. C. Goldstein Influential?

Ellie J. C. Goldstein's Published Works

Published Works

What Schools Are Affiliated With Ellie J. C. Goldstein?

Ellie J. C. Goldstein's AcademicInfluence.com Rankings